Income statement
CAD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 54M | 28M | 14M | 7M | 7M |
| Gross Profit | 13M | 6M | 4M | 1M | 1M |
| Operating Income | -17M | -20M | -13M | -4M | -4M |
| EBITDA | -11M | -16M | -11M | -4M | -3M |
| Net Income | -28M | -26M | -14M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-99.79%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Valeo Pharma Inc. (VPHIF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +94.3%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +94.3%, EPS 0.0%, free cash flow +40.0% with operating margin -32.0% and ROIC -67.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VPHIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VPHIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VPHIF Max Drawdown
-99.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VPHIF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.6M
-12.0% YoY
FY Net Income
-$3.6M
+24.1% YoY
Free Cash Flow
-$3.3M
+51.5% YoY
Revenue Growth
+94.3%
EPS Growth
+0.0%
Gross Margin
24.3%
Net Margin
-51.6%
Income statement
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 54M | 28M | 14M | 7M | 7M |
| Gross Profit | 13M | 6M | 4M | 1M | 1M |
| Operating Income | -17M | -20M | -13M | -4M | -4M |
| EBITDA | -11M | -16M | -11M | -4M | -3M |
| Net Income | -28M | -26M | -14M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 23M | 2M | 3M | 335K |
| Total Assets | 41M | 58M | 21M | 11M | 6M |
| Total Liabilities | 82M | 76M | 19M | 8M | 6M |
| Shareholder Equity | -40M | -18M | 2M | 3M | -22K |
| Total Debt | 65M | 61M | 8M | 3M | 1M |
| Net Debt | 58M | 39M | 6M | 426K | 666K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+56.5% YoY
Capital Expenditures
945K
+32.7% YoY
Free Cash Flow
3M
+51.5% YoY
Key ratios
Gross Margin
24.3%
Operating Margin
-32.0%
Net Margin
-51.6%
ROE
95.6%
Debt / Equity
-1.62x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.